TP53 and lung carcinoma: Our study demonstrates LT1-3’s multifunctionality, its intrinsic antitumor activity, its enhancement of cisplatin efficacy in many TP53 mutant lung cancer cells, its reduction in cisplatin-induced side effects, and its non-toxicity to normal cells.